Breakthrough Bispecific Nanobody Targeting GPC3 and TNFRSF9 for Colorectal Cancer Therapy

VHH-P384 is a novel humanized nanobody therapeutic specifically engineered to target glypican 3 (GPC3) and TNF receptor superfamily member 9 (TNFRSF9). Currently advancing through the Biological Testing phase, this innovative program utilizes a bispecific approach to engage critical tumor-associated antigens, offering a promising pathway for the treatment of colorectal cancer. By combining high specificity with advanced modular design, VHH-P384 is positioned at the forefront of next-generation biologic therapies that address key mechanisms underlying colorectal cancer progression and immune modulation.

Licensing Opportunity

VHH-P384 is available for out-licensing and collaborative development. We welcome partnerships from industry and institutional collaborators interested in advancing this novel bispecific nanobody program targeting GPC3 and TNFRSF9 in colorectal cancer.

Development Phase

Modality

VHH-P384 is a bispecific antibody fusion construct, composed of two polypeptide chains. Each chain includes an antibody-derived binding fragment targeting human GPC3, fused seamlessly with an inert human IgG1 Fc domain, further linked to a single-domain antibody against human TNFRSF9. The addition of the YTE mutation in the Fc CH2 region is designed to optimize pharmacokinetic properties. Leveraging the structural advantages of nanobody technology—such as reduced molecular weight, improved tissue penetration, and inherent stability—VHH-P384 holds promise for superior tumor infiltration and enhanced target engagement in colorectal cancer tissues, potentially resulting in more effective antitumor responses compared to conventional antibody constructs.

Target

GPC3 is a membrane-associated heparan sulfate proteoglycan frequently overexpressed in tumor cells, while TNFRSF9 is a costimulatory immune receptor primarily found on activated T cells and natural killer cells. GPC3 serves as a tumor antigen in various malignancies, including colorectal cancer, making it a valuable target for precision therapeutics aimed at selective tumor cell recognition. TNFRSF9 plays a pivotal role in T cell activation and survival, thereby modulating antitumor immune responses. The concurrent targeting of GPC3 and TNFRSF9 allows VHH-P384 to leverage both tumor specificity and immune activation mechanisms. This dual-target strategy is particularly valuable in colorectal cancer, where immunosuppression and tumor heterogeneity present significant challenges. By engaging GPC3 for tumor localization and TNFRSF9 for immune system activation, VHH-P384 offers strategic advantages in enhancing therapeutic efficacy and overcoming resistance mechanisms.

Mechanism of Action

VHH-P384 exerts its activity through dual, bispecific engagement of GPC3 and TNFRSF9. By binding GPC3 on tumor cells, VHH-P384 selectively localizes the therapeutic effect to malignant tissue. Simultaneously, targeting TNFRSF9 on immune cells potentiates costimulatory signaling pathways, enhancing T cell proliferation and effector functions within the tumor microenvironment. The fusion of single-domain nanobody fragments further augments specificity and versatility, allowing potential adaptation into other modalities such as antibody-drug conjugates or next-generation multispecific constructs. Through precise modulation of both tumor and immune components, VHH-P384 addresses critical pathways implicated in colorectal cancer pathogenesis and progression.

Colorectal Cancer

Colorectal cancer is among the most commonly diagnosed malignancies worldwide, representing a significant source of cancer-related morbidity and mortality. Its development is associated with environmental, genetic, and lifestyle factors, and incidence rates continue to rise in many regions. Conventional treatment strategies include surgical resection, chemotherapy, radiotherapy, and more recently, targeted therapies and immunotherapies. While these approaches have led to improved outcomes for some patients, limitations persist, such as chemoresistance, disease recurrence, and the inability to address tumor heterogeneity. Notably, a substantial unmet need remains for effective therapies in advanced and treatment-refractory cases. Innovative therapeutics like VHH-P384, which combine tumor antigen specificity with immune costimulation, present a promising frontier for the management of colorectal cancer. By addressing both cancer cell targeting and overcoming immune evasion, VHH-P384 has the potential to provide a new option for patients with limited responses to standard treatments.